Cardiogen is a short peptide bioregulator believed to have an affinity for cardiac (heart) tissue. It was developed by researchers studying how small protein fragments from specific organs might regulate gene activity and cell function in those same organs. It is a research-use-only compound and is not approved as a medicine or supplement anywhere in the world.[5]

How does Cardiogen work?

Researchers believe Cardiogen works by interacting with cellular signaling pathways in heart and vascular tissue. One preclinical study found that rather than directly destroying cells, Cardiogen appeared to act through the vascular (blood vessel) network of tissue, influencing apoptosis — the process of programmed cell death — indirectly.[5] The precise molecular mechanism in cardiac cells is still under investigation.

What is Cardiogen used for in research?

In research, Cardiogen is being studied for its potential effects on cardiac cell support, regulation of apoptosis, age-related heart tissue changes, and vascular biology. One animal study demonstrated dose-dependent effects on tumor cell death via a vascular mechanism.[5] It is also of interest in the broader context of understanding how molecular signals affect heart tissue health.[1]

How is Cardiogen dosed?

There is no standardized human dosing protocol for Cardiogen. Doses used in preclinical research have varied by study design and animal model. Researchers are encouraged to consult the dosage chart on this page for a summary of doses explored in available literature, and to use the calculator tool for preparation planning. All use should occur within an approved institutional research framework.

How do you reconstitute Cardiogen?

Cardiogen powder is typically reconstituted by slowly adding bacteriostatic water or sterile saline to the vial and gently swirling — never shaking — until fully dissolved. Once reconstituted, it should be stored refrigerated at 2–8 °C and used within a few weeks. Unmixed powder should be kept frozen at around −20 °C, away from light and moisture. Follow your institution's specific handling protocols.

Cardiogen has only been evaluated in limited preclinical (animal) research. One study noted it did not appear to have a direct toxic cytostatic effect on cells, suggesting a relatively indirect mechanism of action.[5] However, no comprehensive human safety data exists. It is not approved for human use, and any research involving this compound must be conducted under appropriate institutional and regulatory oversight.

Cardiogen Dosage Chart, Protocol & Calculator

A cardiac peptide bioregulator.

Objetivo	Dosis	Frecuencia	Duración	Evidencia	Fuente
Los datos de dosis citados de este compuesto se están compilando.

What is Cardiogen?

Cardiogen is a short peptide bioregulator — a tiny protein fragment — that was originally isolated from heart tissue. It belongs to a family of compounds sometimes called cytomedins or peptide bioregulators, developed largely by researchers at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. The idea behind bioregulators is that small peptides derived from specific organs may help regulate the function of those same organs. Cardiogen, as the name suggests, is aimed at cardiac (heart) tissue. It is strictly a research-use compound and is not approved as a medicine anywhere. Everything on this page refers to laboratory and preclinical research only.

How Cardiogen Works

Think of your heart cells like workers in a factory. Over time — especially with age or disease — those workers start slowing down, making mistakes, or dying off too soon. Bioregulator peptides like Cardiogen are theorized to act like little instruction slips delivered to the cell nucleus, nudging genes back toward a healthier pattern of activity.

At a molecular level, short peptides can interact with DNA-binding proteins, potentially influencing which genes are switched on or off in heart cells. Researchers are particularly interested in whether this kind of signaling can support normal cell turnover, reduce excessive cell death (apoptosis), and maintain the structural integrity of cardiac tissue. One study also found that Cardiogen acts through the vascular network of tissue rather than by directly killing cells — pointing to an indirect, regulatory mechanism.^[5]

What the Research Shows

Published research on Cardiogen itself is limited but gives some early clues about how it behaves in living systems.

Tumor model study (2009): Scientists at the St. Petersburg Institute tested Cardiogen in aged rats that had been implanted with M-1 sarcoma tumors. They found that Cardiogen injections increased the rate of apoptosis (programmed cell death) in tumor cells in a dose-dependent way. Importantly, the researchers noted that this effect was not a direct cytostatic action — meaning Cardiogen wasn't simply poisoning the tumor cells directly. Instead, the evidence pointed to Cardiogen working through the tumor's blood vessel network.^[5] While this was a tumor model, the finding reveals something fundamental about how Cardiogen may influence tissue biology.

It is worth noting that much of the broader scientific conversation around cardiac bioregulators happens within the context of serious heart conditions. For example, researchers studying conditions like transthyretin amyloid cardiomyopathy (ATTR-CM) — a progressive, often fatal disease where abnormal proteins accumulate in heart tissue — have emphasized how poorly understood cardiac biology at the cellular level still is, and how large the gap remains between basic science and effective treatment.^[1]^[2] Cardiac amyloidosis research has highlighted the complexity of the heart's response to protein misfolding and the need for novel approaches to cardiac cell support.^[4] Cardiogen research exists within this broader landscape of trying to understand and support heart tissue health.

Additionally, understanding how cardiac cells regulate electrical stability — for instance, through ion channels involved in conditions like Long QT Syndrome — underscores how sensitive heart tissue is to molecular-level signals.^[6] Peptide bioregulators like Cardiogen are being studied partly because of this sensitivity.

What Cardiogen Is Being Studied For

In research settings, Cardiogen is being explored for its potential roles in:

Cardiac cell support — whether it can help aging or stressed heart cells maintain healthier function
Apoptosis regulation — understanding how it influences programmed cell death in cardiac and other tissues^[5]
Gerontology — its potential relevance to age-related decline in heart tissue
Vascular biology — how it interacts with blood vessel networks inside tissues^[5]

None of these areas represent approved medical uses. All research is preclinical or at very early stages.

How Cardiogen Is Dosed in Research

Dosing protocols for Cardiogen vary across the small body of published literature, and no standardized human research protocol exists. Because this is a research-only compound, investigators typically work from preclinical animal data and adjust based on study design. To see how doses have been explored in the available research, refer to the dosage chart on this page. If you need to calculate quantities for a specific study preparation, use the calculator tool available on this site. Always follow institutional guidelines and work within an approved research framework.

Mixing and Storing Cardiogen

Cardiogen, like most research peptides, typically arrives as a lyophilized powder — meaning it has been freeze-dried for stability during shipping and storage. Before use in a research setting, it must be reconstituted by adding a sterile solvent, most commonly bacteriostatic water or sterile saline, slowly and gently to the vial. Avoid shaking; swirl carefully until the powder fully dissolves. Once mixed, the solution should be stored at 2–8 °C (standard refrigerator temperature) and used within a reasonable timeframe — typically within a few weeks, depending on the solvent used. Unmixed powder should be kept frozen (around −20 °C) away from light and moisture. Always label vials clearly with the date of reconstitution and concentration. These are general research-handling guidelines; always follow your institution's specific protocols.

Sources

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). — Global heart, 2023. PMID 37901600.
Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. — European heart journal, 2026. PMID 41055898.
Update on CardioGen-82. — Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012. PMID 22393230.
[Cardiac amyloidosis]. — Annales de pathologie, 2021. PMID 33422349.
Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. — Bulletin of experimental biology and medicine, 2009. PMID 20396706.
Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. — European heart journal, 2021. PMID 34505893.

Cardiogen Guía & Tabla de Dosis